Successful Treatment of Tumor Necrosis Factor Receptor–Associated Periodic Syndrome With Canakinumab
Authors: Maria Giuseppina Brizi, Mauro Galeazzi, Orso Maria Lucherini, Luca Cantarini, Rolando Cimaz
Journal: Annals of Internal Medicine (2012)

Letters19 June 2012Successful Treatment of Tumor Necrosis Factor Receptor–Associated Periodic Syndrome With CanakinumabMaria Giuseppina Brizi, MD, Mauro Galeazzi, MD, Orso Maria Lucherini, PhD, Luca Cantarini, MD, PhD, and Rolando Cimaz, MDMaria Giuseppina Brizi, MDFrom University of Siena, 53100 Siena, Italy, and University of Florence, 50139 Florence, Italy.Search for more papers by this author, Mauro Galeazzi, MDFrom University of Siena, 53100 Siena, Italy, and University of Florence, 50139 Florence, Italy.Search for more papers by this author, Orso Maria Lucherini, PhDFrom University of Siena, 53100 Siena, Italy, and University of Florence, 50139 Florence, Italy.Search for more papers by this author, Luca Cantarini, MD, PhDFrom University of Siena, 53100 Siena, Italy, and University of Florence, 50139 Florence, Italy.Search for more papers by this author, and Rolando Cimaz, MDFrom University of Siena, 53100 Siena, Italy, and University of Florence, 50139 Florence, Italy.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-156-12-201206190-00027 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Tumor necrosis factor (TNF) receptor–associated periodic syndrome (TRAPS) is characterized by prolonged fever episodes with periorbital edema, migratory erythematous plaques, myalgia, and serositis (1). Renal amyloidosis is the most serious long-term complication, with prevalence ranging from 14% to 25% (1). As the most common autoinflammatory disorder related to an autosomal dominant gene, TRAPS is caused by mutations in the TNFRSF1A gene, which encodes the 55-kDa receptor for TNF-α (2). These mutations negatively affect both gene expression and function (2, 3).Treating TRAPS is more challenging than treating other autoinflammatory syndromes because of its genetic heterogeneity and protean clinical phenotype. ...References1. Hull KM, Drewe E, Aksentijevich I, Singh HK, Wong K, McDermott EM, et al. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore). 2002;81:349-68. [PMID: 12352631] CrossrefMedlineGoogle Scholar2. McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999;97:133-44. [PMID: 10199409] CrossrefMedlineGoogle Scholar3. Lobito AA, Kimberley FC, Muppidi JR, Komarow H, Jackson AJ, Hull KM, et al. Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood. 2006;108:1320-7. [PMID: 16684962] CrossrefMedlineGoogle Scholar4. Gattorno M, Pelagatti MA, Meini A, Obici L, Barcellona R, Federici S, et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 2008;58:1516-20. [PMID: 18438813] CrossrefMedlineGoogle Scholar5. Obici L, Meini A, Cattalini M, Chicca S, Galliani M, Donadei S, et al. Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis [Letter]. Ann Rheum Dis. 2011;70:1511-2. [PMID: 21173015] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Maria Giuseppina Brizi, MD; Mauro Galeazzi, MD; Orso Maria Lucherini, PhD; Luca Cantarini, MD, PhD; Rolando Cimaz, MDAffiliations: From University of Siena, 53100 Siena, Italy, and University of Florence, 50139 Florence, Italy.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byBiologic Therapies for the Management of Cutaneous Findings in Genodermatoses: A ReviewTRAPS bei Kindern und JugendlichenOff-Label Use of Biologics in Rheumatological DisordersReal-Life Indications of Interleukin-1 Blocking Agents in Hereditary Recurrent Fevers: Data From the JIRcohort and a Literature ReviewTRAPS bei Kindern und JugendlichenRevisiting TNF Receptor-Associated Periodic Syndrome (TRAPS): Current PerspectivesAutoinflammatory Diseases in the Geriatric PopulationAutoinflammatory Disorders: A Review and Update on Pathogenesis and TreatmentThe TNF Receptor-Associated Autoinflammatory Syndrome (TRAPS)Inflammasome-Dependent Cytokines at the Crossroads of Health and Autoinflammatory DiseaseThe TNF Family of Ligands and Receptors: Communication Modules in the Immune System and BeyondLa fièvre récurrente liée au récepteur 1 du TNF ( TNF receptor associated periodic syndrome – TRAPS)Tumor necrosis factor-associated periodic syndrome in adultsCanakinumab for the treatment of TNF-receptor associated periodic syndrome (TRAPS)Efficacy and safety of anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) complicated by severe renal failure: a report after long-term follow-up and review of the literatureCanakinumab for the treatment of TNF-receptor associated periodic syndromePotential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin DiseasesCanakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II studyA Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational StudySystemic and organ involvement in monogenic autoinflammatory disorders: a global review filtered through internists’ lensTranslationale Forschung in der pädiatrischen RheumatologieModulating Inflammatory CytokinesCanakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS)From bench to bedside and back again: translational research in autoinflammationTumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronateAutoimmunity and autoinflammation as the yin and yang of idiopathic recurrent acute pericarditisInterleukin-1 as a Common Denominator from Autoinflammatory to Autoimmune Disorders: Premises, Perils, and PerspectivesA Case Presenting with the Clinical Characteristics of Tumor Necrosis Factor (TNF) Receptor-associated Periodic Syndrome (TRAPS) without TNFRSF1A Mutations Successfully Treated with TocilizumabKey facts and hot spots on tumor necrosis factor receptor‐associated periodic syndromeThe expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: Clinical manifestations and long-term follow-upWorking the endless puzzle of hereditary autoinflammatory disordersUntangling the Web of Systemic Autoinflammatory DiseasesTreating inflammation by blocking interleukin-1 in humansFirst Report of Circulating MicroRNAs in Tumour Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS)Autoinflammatory Diseases in DermatologyInflammasome and cytokine blocking strategies in autoinflammatory disordersMonogenic Autoinflammatory Syndromes: State of the Art on Genetic, Clinical, and Therapeutic IssuesBiological Treatments: New Weapons in the Management of Monogenic Autoinflammatory Disorders 19 June 2012Volume 156, Issue 12Page: 907-908KeywordsAmyloidosisC-reactive proteinsErythrocyte sedimentation rateFeversInflammationMutationMyalgiaReceptor antagonist therapyRenal diseasesTumor necrosis factor ePublished: 19 June 2012 Issue Published: 19 June 2012 Copyright & PermissionsCopyright © 2012 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...